A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Public ClinicalTrials.gov record NCT07562087. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.
Study identification
- NCT ID
- NCT07562087
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 722 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2026 (Actual)
- Primary completion
- Oct 2027 (Estimated)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Jul 9, 2026
2026 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 7
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Pikesville | Maryland | 21208 | — |
| Study Site | Brookline | Massachusetts | 02445 | — |
| Study Site | Fall River | Massachusetts | 02723 | — |
| Study Site | Minneapolis | Minnesota | 55402 | — |
| Study Site | Marlboro | New Jersey | 07746 | — |
| Study Site | Albany | New York | 12205 | — |
| Study Site | Binghamton | New York | 13905 | — |
| Study Site | Buffalo | New York | 14217 | — |
| Study Site | East Syracuse | New York | 13057 | — |
| Study Site | Middletown | New York | 10941 | — |
| Study Site | New York | New York | 10036 | — |
| Study Site | Rochester | New York | 14609 | — |
| Study Site | Erie | Pennsylvania | 16508 | — |
| Study Site | Hatboro | Pennsylvania | 19040 | — |
| Study Site | Philadelphia | Pennsylvania | 19107 | — |
| Study Site | Pittsburgh | Pennsylvania | 15236 | — |
| Study Site | Pottstown | Pennsylvania | 19464 | — |
| Study Site | West Chester | Pennsylvania | 19380 | — |
| Study Site | Warwick | Rhode Island | 02886 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07562087, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07562087 live on ClinicalTrials.gov.